Background
Colorectal carcinoma (CRC) is frequently typified by chronic inflammation and high levels of immunosuppression that render it resistant to immunotherapy. The multimodal immunostimulatory mechanisms of oncolytic virotherapy make it an attrac…
Background
CD19-targeting chimeric antigen receptor T-cells (CAR-T) and blinatumomab represent two leading immunotherapies for relapsed/refractory B cell acute lymphoblastic leukemia (r/r B-ALL). Despite sharing the same target, their differential cli…
Background
Oncolytic viruses represent a promising immunotherapeutic strategy for converting pancreatic and other immunologically cold tumors. While their ability to stimulate innate immune signaling and promote antitumor immunity is established, mech…
Background
Novel therapies to prevent lethal castration-resistant prostate cancer in response to standard-of-care androgen deprivation therapy (ADT) are required. Unfortunately, most prostate cancers are “immune cold” and fail to respond to checkpoint…
Background
Patients with advanced non-small cell lung cancer who progress on immune checkpoint inhibitors (ICIs) face limited options and poor survival. Aglatimagene besadenovec (CAN-2409), a replication-defective adenoviral vector encoding herpes sim…
Background
Identifying reproducible biomarkers associated with treatment outcomes remains a major unmet clinical need in advanced non-small cell lung cancer (NSCLC). METLUNG evaluated whether plasma metabolomic profiling, alone or combined with clinic…
Background
Patients with metastatic non-small cell lung cancer (NSCLC) or extensive-stage small cell lung cancer (ES-SCLC) have poor prognosis and survival with current standard of care. Several checkpoint inhibitor combinations have been evaluated cl…
Despite curative-intent nephrectomy, approximately one-third of patients with localized clear cell renal cell carcinoma (ccRCC) eventually experience disease recurrence due to occult minimal residual disease. Although adjuvant immune checkpoint blocka…
Adrenocortical carcinoma (ACC) is a rare and highly aggressive endocrine malignancy with limited treatment options and poor prognosis. Venous tumor thrombus (VTT) is a common complication associated with ACC progression, yet the cellular and molecular…
Thymic carcinoma is a rare, aggressive malignancy with limited treatment options. First-line platinum-based chemotherapy yields response rates below 40%, and immune checkpoint inhibitors have shown inconsistent efficacy. Ivonescimab, a programmed cell…
